114 related articles for article (PubMed ID: 7613732)
1. Trial objectives and end points for measuring the efficacy of HIV vaccines.
Hoff R; Barker LF
Infect Agents Dis; 1995 Jun; 4(2):95-101. PubMed ID: 7613732
[TBL] [Abstract][Full Text] [Related]
2. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
[TBL] [Abstract][Full Text] [Related]
3. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
[TBL] [Abstract][Full Text] [Related]
4. HIV vaccine development and evaluation: realistic expectations.
Heyward WL; MacQueen KM; Goldenthal KL
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S205-10. PubMed ID: 9814945
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible?
Excler JL; Beyrer C
J Hum Virol; 2000; 3(4):193-214. PubMed ID: 10990167
[TBL] [Abstract][Full Text] [Related]
6. Cold shower for AIDS vaccines.
Nat Med; 2007 Dec; 13(12):1389-90. PubMed ID: 18064013
[No Abstract] [Full Text] [Related]
7. Fifty volunteer for live-vaccine trial.
James JS
AIDS Treat News; 1997 Oct; (No 280):1-2. PubMed ID: 11364735
[TBL] [Abstract][Full Text] [Related]
8. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
Francis DP; Gregory T; McElrath MJ; Belshe RB; Gorse GJ; Migasena S; Kitayaporn D; Pitisuttitham P; Matthews T; Schwartz DH; Berman PW
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S325-31. PubMed ID: 9814961
[TBL] [Abstract][Full Text] [Related]
9. HIV vaccines under study.
Ravanfar P; Mendoza N; Satyaprakash A; Jordan BI
Dermatol Ther; 2009; 22(2):158-67. PubMed ID: 19335727
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
11. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
12. An HIV vaccine: how and when?
Esparza J
Bull World Health Organ; 2001; 79(12):1133-7. PubMed ID: 11799445
[TBL] [Abstract][Full Text] [Related]
13. Current HIV clinical trial design issues.
Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of primate models for AIDS.
Haigwood NL
AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
[TBL] [Abstract][Full Text] [Related]
15. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
16. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
17. Preparations for HIV vaccine efficacy trials. Vaccine selection guidelines. National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Barker LF
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S295-6. PubMed ID: 7865322
[No Abstract] [Full Text] [Related]
18. Tepid endorsement for HIV vaccine trial.
Science; 1995 Feb; 267(5200):966. PubMed ID: 7863340
[No Abstract] [Full Text] [Related]
19. First AIDS vaccine trial launched.
Science; 1998 Jun; 280(5370):1697. PubMed ID: 9660708
[No Abstract] [Full Text] [Related]
20. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
